Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded
biopharmaceutical firm that focuses on the design and development of novel
broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in
New Haven, Connecticut.
In mid-2011,
Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.
[ It was renamed Melinta Therapeutics in 2013.]
One of its products, delafloxacin
Delafloxacin sold under the brand name Baxdela among others, is a fluoroquinolone antibiotic used to treat acute bacterial skin and skin structure infections.
Medical use
Delafloxacin is indicated to treat adults with acute bacterial skin and s ...
(Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006, was approved by the FDA
The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food s ...
in 2017.
As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[
Melinta shredded off its discovery research team in late 2018.]
It also moved its headquarters from New Haven to in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.
On April 2020, it was transferred to affiliates of its creditor Deerfield Management.
References
External links
*
{{coord, 40.80164, -74.45860, type:landmark_globe:earth_region:US-NJ, display=title
Pharmaceutical companies based in New Jersey
Pharmaceutical companies of the United States
Pharmaceutical companies established in 2000
Companies that filed for Chapter 11 bankruptcy in 2019
Morristown, New Jersey
Companies based in Morris County, New Jersey
2000 establishments in Connecticut